Armata Pharmaceuticals, Inc. insider trading

Every open-market purchase and sale by Armata Pharmaceuticals, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

No open-market insider trades reported in the last five years.

Does following Armata Pharmaceuticals, Inc.’s insiders pay?

From March 18, 2015 to April 1, 2022, 8 insiders reported 12 open-market purchases and 1 sale not made under a pre-set plan in Armata Pharmaceuticals, Inc. Twelve months after each purchase was reported, the shares were −60.6% against the S&P 500 on average (median −62.8%), over 5 purchases with a full year of prices; 0% beat the index. That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on October 7, 2015 into $1,017 by November 2, 2026, −18.7% a year. It held shares 28% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $14,898 (+3.7% a year), and held throughout $45,378 (+14.7%).

Copying Armata Pharmaceuticals, Inc.'s insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Armata Pharmaceuticals, Inc.'s insiders from October 7, 2015, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 28% of the time.

Armata Pharmaceuticals, Inc.: each insider's record
Insider	Role	Purchases	12 months after their purchases	Beat the S&P 500	Sales	12 months after their sales	Latest report
Innoviva Strategic Opportunities LLC	Director	3	−43.7% (1)	0%	0	—	February 11, 2022
Innoviva, Inc.	Director	3	−47.2% (2)	0%	0	—	April 1, 2022
Cook Jeremy Curnock	Director	2	—	—	0	—	March 26, 2018
Drapeau Louis	Director	1	−83.7% (1)	0%	0	—	October 7, 2015
Intrexon Corp	10% owner	1	—	—	0	—	March 18, 2015
Kirk Randal J	10% owner	0	—	—	1	—	December 29, 2016
Perry Michael S	Director	1	—	—	0	—	March 26, 2018
Salka Michael Scott	Chief Executive Officer	1	−81.4% (1)	0%	0	—	October 6, 2015

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Armata Pharmaceuticals, Inc.

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Armata Pharmaceuticals, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 1 buying crowd with six months of prices, it averaged −50.1% against the index. One company's history is too short to judge by; the test across every company is the better guide.

Month	Crowd	3 months on, vs S&P 500	6 months	12 months
October 30, 2015	2 buying	−34.9%	−50.1%	−84.0%

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Total returns from the month end; past patterns are not a forecast.

← Back to Armata Pharmaceuticals, Inc. · Funds · Politicians